Sarah Bencardino

Aug 23, 2024 | mdpi.com | Jacopo Fanizza |Sarah Bencardino |Mariangela Allocca |Federica Furfaro

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 31, 2024 | preprints.org | Jacopo Fanizza |Sarah Bencardino |Mariangela Allocca |Federica Furfaro

PreprintReviewVersion 1This version is not peer-reviewedVersion 1: Received: 31 July 2024 / Approved: 31 July 2024 / Online: 31 July 2024 (12:01:23 CEST)Fanizza, J.; Bencardino, S.; Allocca, M.; Furfaro, F.; Zilli, A.; Parigi, T. L.; Fiorino, G.; Peyrin-Biroulet, L.; Danese, S.; D’Amico, F. Inflammatory Bowel Disease and Colorectal Cancer. Preprints 2024, 2024072568. https://doi.org/10.20944/preprints202407.2568.v1Fanizza, J.; Bencardino, S.; Allocca, M.; Furfaro, F.; Zilli, A.; Parigi, T.

Mar 7, 2024 | mdpi.com | Francesca Bernardi |Ferdinando D’Amico |Sarah Bencardino |Ilaria Faggiani

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Jul 30, 2023 | mdpi.com | Ferdinando D’Amico |Francesca Bernardi |Sarah Bencardino |Ilaria Faggiani

Abstract:Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that negatively impacts patients’ quality of life. In the last decades, the therapeutic options available for the management of patients with moderate to severe UC have increased significantly, including not only biological drugs but also small molecules. However, there is a persistent need to develop new drugs that act on new targets while minimizing the risk of adverse events.